Non-viral delivery of ribozymes for cancer gene therapy

Bibliography

• GUERRIER-TAKADA C, CARDINER K, MARCH T et al.: The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell (1983) 35:849–857.
   PubMed Web of Science ®Google Scholar
• ZAUG AJ, CECH T: The intervening sequence RNA of Tetrahymena is an enzyme. Science (1986) 231:470–475.
   PubMed Web of Science ®Google Scholar
• BAGHERI S, KASHANI-SABET M: Ribozymes in the age of molecular therapeutics. Curc Ma Med. (2004) 4:489–506.
   PubMed Web of Science ®Google Scholar
• KASHANI-SABET M, SCANLON KJ: Application of ribozymes to cancer gene therapy. Cancer Gene Ther. (1995) 2:213–225.
   PubMed Web of Science ®Google Scholar
• PANTEL K, BRAKENHOFF RH: Dissecting the metastatic cascade. Nat. Rev Cancer (2004) 4:448–456.
   PubMed Web of Science ®Google Scholar
• CHAMBERS AF, GROOM AC, MACDONALD IC: Dissemination and growth of cancer cells in metastatic sites. Nat. Rev Cancer (2002) 2:563–572.
   PubMed Web of Science ®Google Scholar
• USMAN N, BLATT LM: Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest. (2000) 106:1197–1202.
   PubMed Web of Science ®Google Scholar
• FERRARA N, HILLAN KJ, GERBER HP, NOVOTNY W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev Drug Discov. (2004) 3:391–400.
   PubMed Web of Science ®Google Scholar
• KIM KJ, LI B, WINER J et al: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth M vivo. Nature (1993) 362:841–844.
   PubMed Web of Science ®Google Scholar
• MILLAUER B, SHAWVER LK,PLATE KH et al.: Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature (1994) 367:576–579.
   Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl. I Med. (2004) 350:2335–2342.
   PubMed Web of Science ®Google Scholar
• WINCOTT F, DIRENZO A, SHAFFER C et al.: Synthesis, deprotection, analysis and purification of RNA and ribozymes. Nucleic Acids Res. (1995) 23:2677–2684.
   PubMed Web of Science ®Google Scholar
• SANDBERG JA, BOUHANA KS, GALLEGOS AM et al.: Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse. AntisenseNucleic Acid Drug Dev. (1999) 9:271–277.
   PubMedGoogle Scholar
• SANDBERG JA, SPROUL CD, BLANCHARD KS et al.: Acute toxicology and pharmacokinetic assessment of a ribozyme (ANGIOZYME) targeting vascular endothelial growth factor receptor mRNA in the cynomolgus monkey. Antisense Nucleic Add Drug Dev. (2000) 10:153–162.
   PubMedGoogle Scholar
• PAVCO PA, BOUHANA KS, GALLEGOS AM et al.: Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer Res. (2000) 6:2094–2103.
   PubMed Web of Science ®Google Scholar
• •This study demonstrated antiturnour activity for Angiozyme in preclinical models of tumour metastasis.
   Google Scholar
• SANDBERG JA, PARKER VP,BLANCHARD KS et al.: Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers. J. Clin. Pharmacol (2000) 40:1462–1469.
   Google Scholar
• VENOOK A, HURWITZ H,CUNNINGHAM C et al.: Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: Results of a Phase II trial of a ribozyme targeting the pre-mRNA of VEGFR-1 (angiozyme), in combination with chemotherapy. Proceedings of the 39th Annual Meeting of the American Socieo, of Clinical Oncology Chicago, USA (31 May -3 June 2003) Abstract 1025.
   Google Scholar
• •This study evaluated the biological and potential clinical efficacy of Angiozyme in a clinical trial of colorectal carcinoma patients.
   Google Scholar
• SLAMON DJ, GODOLPHIN W,JONES LA et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 244:707–712.
   PubMed Web of Science ®Google Scholar
• MUSS HB, THOR AD, BERRY DA et al:c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl. J. Med. (1994) 330:1260–1266.
   PubMed Web of Science ®Google Scholar
• SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HERZ for metastatic breast cancer that overexpresses HERZ. N Engl. J. Med. (2001) 344:783–792.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, ANDEREGG B, OHKAWA T et al.: Adenovirus-mediated ribozyme targeting of HER-2/neu inhibits M vivogrowth of human breast cancer cells. Gene Ther. (2000) 7:241–248.
   PubMed Web of Science ®Google Scholar
• JUHL H, DOWNING SG,WELLSTEIN A, CZUBAYKO F: HER-2/ neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/ neu by ribozyme targeting. j. Biol. Chem. (1997) 272:29482–29486.
   Google Scholar
• WIECHEN K, ZIMMER C, DIETEL M: Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein. Cancer Gene Ther. (1998) 5:45–51.
   PubMed Web of Science ®Google Scholar
• GELMON KA, CHIA S, D'ALOISIO et al.: A Phase I study of HERZYMETm, an anti-HER2 ribozyme, in patients with HERZ overexpressing cancers. Proceedings of the 94th Annual Meeting of the American Association for Cancer Research. Toronto, Canada (11–14 July 2003) Abstract 6443.
   Google Scholar
• AIGNER A, FISCHER D, MERDAN T, BRUS C, KISSEL T, CZUBAYKO F: Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther. (2002) 24:1700–1707.
   Google Scholar
• •This study used a PEI-based approach for ribozyme delivery to tumours.
   Google Scholar
• SLEPUSHKIN V, SIMOES S, DE LIMA MC, DUZGUNES N: Sterically stabilized pH-sensitive liposomes. Methods Enzymol (2004) 387:134–147.
   PubMed Web of Science ®Google Scholar
• SANDRIN V, RUSSELL SJ, COSSET FL: Targeting retroviral and lentiviral vectors. Curc Top. Microbiol Immunol (2003) 281:137–178.
   PubMed Web of Science ®Google Scholar
• IMPERIALE MJ, KOCHANEK S: Adenovirus vectors: biology, design, and production. Curc Top. Microbiol Immunol. (2004) 273:335–357.
   PubMed Web of Science ®Google Scholar
• YANG Y, NUNES FA, BERENCSI K, FURTH E, GONCZOL E, WILSON JM: Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Nati Acad. Sci. USA (1994) 91:4407–4411.
   PubMed Web of Science ®Google Scholar
• WILSON JM: Adenoviruses as gene-delivery vehicles. N Engl. J. Med. (1996) 334:1185–1187.
   PubMed Web of Science ®Google Scholar
• TU G, KIRCHMAIER AL, LIGGITT D et al.: Non-replicating Epstein-Barr virus-based plasmids extend gene expression and can improve gene therapy in vivo. J. Biol. Chem. (2000) 275:30408–30416.
   PubMed Web of Science ®Google Scholar
• •This study identified a novel EBV-based delivery approach for systemic gene delivery.
   Google Scholar
• NOSRATI M, LI S, BAGERI S et al.:Anti-tumor activity of systemically delivered ribozymes targeting murine telomerase RNA. Gin. Cancer Res. (2004) 10:4983–4990.
   Web of Science ®Google Scholar
• •This study identified a role for telomerase in the metasatic progression of melanoma in a murine model.
   Google Scholar
• GILMORE TD: The Rel/NF-kappa B/I kappa B signal transduction pathway and cancer. Cancer Treat. Res. (2003) 115:241–265.
   PubMedGoogle Scholar
• SUN SC, XIAO G: Deregulation of NF-kappaB and its upstream kinases in cancer. Cancer Metastasis Rev (2003) 22:404–422.
   Google Scholar
• GRETEN FR, KARIN M: The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. (2004) 206:193–199.
   PubMed Web of Science ®Google Scholar
• KASHANI-SABET M, LIU Y, FONG S et al.: Identification of gene function and functional pathways by systemic plasmid-based ribozyme targeting in adult mice. Proc. Natl. Acad. Sci. USA (2002) 99:3878–3883.
   PubMed Web of Science ®Google Scholar
• ••This study identified a novel role forNF-x13 in the metastatic progression of melanoma using a systemic, plasmid-based delivery approach.
   Google Scholar
• LIU Y, MOUNKES LC, LIGGITT D et al.: Factors influencing the efficiency of cationic liposome-mediated intravenous gene delivery. Nat. Biotechnol. (1997) 15:67–73.
   Google Scholar
• KASHANI-SABET M, SHAIKH L, SAGEBIEL RW et al.: NF-icB in the vascular progression of melanoma. J. Oncol. (2004) 22:617–623.
   Google Scholar
• PIALI L, HAMMEL P, UHEREK C et al.:CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. Cell Biol. (1995) 130:451–460.
   PubMed Web of Science ®Google Scholar
• RITCHIE CK, GIORDANO A, KHALILI K: Integrin involvement in glioblastoma multiforme: possible regulation by NF-kappaB. I Cell. Physiol. (2000) 184:214–221.
   PubMed Web of Science ®Google Scholar
• BOTELLA LM, PUIG-KROGER A, ALMENDRO N et al.: Identification of a functional NF-kappa B site in the platelet endothelial cell adhesion molecule-1 promoter. Immunol. (2002) 164:1372–1378.
   Web of Science ®Google Scholar
• AKIYAMA M, HIDESHIMA T, HAYASHI T et al.: Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. (2003) 63:18–21.
   PubMed Web of Science ®Google Scholar
• YIN L, HUBBARD AK, GIARDINA C: NF-kappa B regulates transcription of the mouse telomerase catalytic subunit. J. Biol. Chem. (2000) 275:36671–36675.
   PubMed Web of Science ®Google Scholar
• SUYAMA E, WADHWAS R,KAMALJIT K et al.: Identification of metastasis-related genes in a mouse model using a library of randomized ribozymes.Biol. Chem. (2004) 279:38083–38086.
   Google Scholar
• •This study used a ribozyme library to identify novel genes involved in tumour metastasis.
   Google Scholar
• KASHANI-SABET M, FUNATO T, FLORENES VA, FODSTAD 0 et al.: Suppression of the neoplastic phenotype in vivo by an anti-rasribozyme. Cancer Res. (1994) 54:900–902.
   Google Scholar
• MAELANDSMO GM, HOVIG E, SKREDE M et al.: Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mtsl) ribozyme. Cancer Res. (1996) 56:5490–5498.
   PubMed Web of Science ®Google Scholar
• CZUBAYKO F, SCHULTE AM, BERCHEM GJ, WELLSTEIN A: Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin.Proc. Nati Acad. Sci. USA (1996) 93:14753-14758.This study used ribozymes to identify a novel role for pleiotrophin in the angiogenic and metastatic phenotype of melanoma.
   Google Scholar
• HUA J, MUSCHEL RJ: Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. (1996) 56:5279–5284.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO H, IRE A, FUKUSHIMA Y et al.: Abrogation of lung metastasis of human fibrosarcoma cells by ribozyme-mediated suppression of integrin alpha 6 subunit expression. Int. Cancer (1996) 65:519–524.
   PubMed Web of Science ®Google Scholar
• KIM SJ, JOHNSON M, KOTERBA K et al.: Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Clin. Cancer Res. (2003) 9:5161–5170.
   PubMed Web of Science ®Google Scholar
• TOKUNAGA T, ABE Y, TSUCHIDA T et al.: Ribozyme mediated cleavage of cell-associated isoform of vascular endothelial growth factor inhibits liver metastasis of a pancreatic cancer cell line. Int. J. Oncol. (2002) 21:1027–1032.
   PubMed Web of Science ®Google Scholar